Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG:6990)

Market Cap	70.04B
Revenue (ttm)	2.06B
Net Income (ttm)	-283.88M
Shares Out	227.27M
EPS (ttm)	-1.28
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	811,904
Average Volume	911,187
Open	285.00
Previous Close	289.00
Day's Range	275.00 - 294.00
52-Week Range	120.20 - 346.00
Beta	n/a
RSI	59.98
Earnings Date	Mar 26, 2025

About HKG:6990

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., a biopharmaceutical company, engages in the research and development, manufacturing, and commercialization of novel drugs to address unmet medical needs in the People’s Republic of China and internationally. The company is developing various drugs to treat breast, non-small cell lung, and gastrointestinal cancer, as well as non-oncology diseases. Its product pipeline includes oncology drug candidates, such as SKB264 (sacituzumab tirumotecan), A166 (trastuzumab botidotin), SKB315, A167 (tagitanl...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2016
• Employees: 1,477
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 6990

Financial Performance

In 2024, HKG:6990's revenue was 1.93 billion, an increase of 25.48% compared to the previous year's 1.54 billion. Losses were -266.77 million, -48.92% less than in 2023.

Financial numbers in CNY